¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"stem cell factor"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
vascular permeability factor
Ç÷°üÅõ°úÀÎÀÚ
virulence factor
µ¶¼ºÀÎÀÚ, ¹ßº´ÀÎÀÚ
virus inhibitory factor
¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
acantholytic cell
°¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
angioimmunoblastic T-cell lymphoma
Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
annular elastotic giant cell granuloma
°í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
accessory cell
º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
antibody-dependent cell-mediated cytotoxicity
Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
antibody-producing cell
Ç×ü»ý»ê¼¼Æ÷
antibody-screening cell
Ç×ü¼±º°Ç÷±¸
antigen-presenting cell
Ç׿øÁ¦½Ã¼¼Æ÷
antigen-reactive cell
Ç׿ø¹ÝÀÀ¼¼Æ÷
antigen-recognizing cell
Ç׿øÀÎÁö¼¼Æ÷
argentaffin cell
ÀºÄ£È¼¼Æ÷
argyrophilic cell
ÀºÄ£È¼¼Æ÷
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
annular elastotic giant cell granuloma
°í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
antibody-dependent cell-mediated cytotoxicity
Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
antibody-producing cell
Ç×ü»ý»ê¼¼Æ÷
antibody-screening cell
Ç×ü¼±º°Ç÷±¸
antigen-presenting cell
Ç׿øÀü´Þ¼¼Æ÷
antigen-reactive cell
Ç׿ø¹ÝÀÀ¼¼Æ÷
antigen-recognizing cell
Ç׿øÀÎÁö¼¼Æ÷
argentaffin cell
ģũ·ÒÀº¼¼Æ÷
argyrophilic cell
ÀºÄ£È¼¼Æ÷
asexual cell
¹«¼º¼¼Æ÷
basal cell adenoma
±âÀú¼¼Æ÷»ùÁ¾, ¹Ù´Ú¼¼Æ÷¾ÏÁ¾
basosqumaous cell acanthoma
±âÀúÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
cell-associated antibody
¼¼Æ÷ºÎÂøÇ×ü
cell-bound antibody
(¢¡cell-fixed antibody) ¼¼Æ÷°áÇÕÇ×ü
cell-fixed antibody
¼¼Æ÷°áÇÕÇ×ü
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
B cell hybridoma
B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
B cell lymphoma
B¼¼Æ÷¸²ÇÁÁ¾
B cell study
B ¼¼Æ÷°Ë»ç
B cell/lymphocyte
B ¼¼Æ÷/¸²ÇÁ±¸
B-cell
ºñ ¼¼Æ÷
C-cell
C ¼¼Æ÷
CD4+ cell
CD4+ ¼¼Æ÷
Cell adhesion molecules
¼¼Æ÷À¯ÂøºÐÀÚ
Chinese hamster ovary tumor cell
Áß±¹ÇÔ½ºÅÍ ³¼Ò¼¼Æ÷, CHO¼¼Æ÷
Graham cell
±×¶óÇÔ¼¼Æ÷
Granulosa cell
°ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
Granulosa cell tumor
°ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
H-9 cell line
H-9 ¼¼Æ÷°è
HeLa cell
Çï¶ó¼¼Æ÷.
HeLa cell
Çï¶ó¼¼Æ÷
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
dose conversion factor
¼±·®º¯È¯°è¼ö
dose limiting factor
¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
dose modifying factor
¼±·®¼ö½Ä°è¼ö
dose-reduction factor
¼±·®°¨¼Ò°è¼ö
drug resistance factor
¾àÁ¦³»¼ºÀÎÀÚ
drug resistance transfer factor
¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
duplicate factor
Áߺ¹ÀÎÀÚ.
early pregnancy factor(EPF)
ÃʱâÀÓ½ÅÀÎÀÚ
edaphic factor
ÅäÁöÀÎÀÚ(ÊÙËöËö).
elongation factor
¿¬ÀåÀÎÀÚ(¡ì×í).
elongation factor
½ÅÀåÀÎÀÚ
enabling factor
ÀÇ·áÀÌ¿ë °¡´É¿äÀÎ.
encephalitogenic factor
³ú¿°À¯¹ßÀÎÀÚ
encephalitogenic factor
³ú¿°À¯¹ßÀÎÀÚ.
endothelium-derived contracting factor (EDCF)
³»ÇǼ¼Æ÷¼º¼öÃàÀÎÀÚ(Ò®ù«á¬øààõâ¥õêì×í)
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
11
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½